ReST Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for RST-101 for the Early Treatment of Post-Traumatic Stress Disorder (PTSD)

PARIS & NEW HAVEN, Conn.--(BUSINESS WIRE)--ReST Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for stress and trauma-related disorders through precision neuropsychiatry, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for RST-101, its lead investigational therapeutic candidate for the early treatment of post-traumatic stress disorder (PTSD). The IND acceptanc